+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immune Checkpoint Inhibitors Market by Indication, Mechanism of Action, End User, Route of Administration - Global Forecast to 2030- Product Image
Immune Checkpoint Inhibitors Market by Indication, Mechanism of Action, End User, Route of Administration - Global Forecast to 2030- Product Image
Sale

Immune Checkpoint Inhibitors Market by Indication, Mechanism of Action, End User, Route of Administration - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888905
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Immune Checkpoint Inhibitors Market grew from USD 10.46 billion in 2024 to USD 11.64 billion in 2025. It is expected to continue growing at a CAGR of 10.91%, reaching USD 19.48 billion by 2030.

Pioneering the Era of Immune Modulation with Checkpoint Blockade

Immune checkpoint inhibitors have redefined the oncological treatment paradigm by harnessing the body’s own defenses to target and eliminate malignant cells. Since the approval of the first CTLA-4 inhibitor, a series of breakthroughs have expanded therapeutic options across multiple indications, turning what was once a niche modality into a cornerstone of modern oncology. These agents modulate inhibitory pathways that cancers exploit to evade immune surveillance, thereby restoring the potency of T-cell-mediated cytotoxicity.

This executive summary distills the pivotal trends and developments steering this dynamic market. It begins with an exploration of foundational scientific advances and regulatory milestones that have propelled checkpoint blockade from experimental therapy to clinical standard of care. Across indications ranging from melanoma to non small cell lung carcinoma and beyond, the advent of combination regimens and next-generation inhibitors has fueled sustained momentum. As you progress through this overview, you will gain clarity on how evolving biology, strategic collaborations, and technological innovations converge to shape competitive landscapes, investment priorities, and patient outcomes.

Revolutionary Shifts Defining Today's Treatment Paradigm

Transformational shifts in oncology have emerged as novel immune checkpoint inhibitors progress from monotherapies to sophisticated combination regimens. Early successes with CTLA-4 blockade laid the groundwork for the rapid ascent of PD-1 and PD-L1 inhibitors, each entry pushing the boundaries of efficacy and safety in refractory and frontline settings. The industry has witnessed a reshuffling of standard protocols as durable responses in melanoma inspired exploration into head and neck malignancies, urothelial cancers, and renal cell carcinoma.

Simultaneously, formulation innovations such as subcutaneous delivery have addressed patient convenience and reduced infusion center burdens, while adaptive trial designs have expedited regulatory pathways. Real-world evidence is now informing dose optimization and treatment sequencing, bridging the gap between controlled studies and everyday clinical practice. Taken together, these shifts underscore a maturing landscape in which precision immuno-oncology is not merely an aspirational goal but an operational reality.

Navigating the 2025 U.S. Tariff Landscape and Its Market Implications

The implementation of revised U.S. tariff schedules in 2025 introduces new complexities to the manufacturing and distribution of immune checkpoint therapies. Increased duties on key biologics and formulation components are poised to exert upward pressure on cost structures, compelling stakeholders to reassess global supply chains. Manufacturers are proactively exploring dual-sourcing strategies, regional production hubs, and negotiations with contract development and manufacturing organizations to mitigate tariff-driven expenditures.

This evolving regulatory environment also impacts pricing negotiations with payers and pharmacy benefit managers. As cost-containment remains a central theme in U.S. healthcare policy, organizations must balance the imperative to maintain competitive net pricing with the need to fund ongoing research and development. In this context, alliances between biotech innovators and established pharmaceutical entities are becoming strategic levers to diffuse risk and optimize resource allocation under the new tariff regime.

Unveiling Critical Insights through Comprehensive Market Segmentation

A rigorous segmentation framework reveals nuanced demand drivers and adoption patterns across indications, mechanisms of action, end users, and administration routes. Within indications such as melanoma or non small cell lung carcinoma, distinctions between first-line and second-line use inform therapeutic positioning and clinical trial prioritization. Further differentiation between combination therapy and monotherapy cohorts offers clarity on regimen-specific safety profiles and reimbursement dynamics.

Mechanistic segmentation underscores the competitive interplay among CTLA-4, PD-1, and PD-L1 agents, each class represented by flagship compounds that command distinct efficacy and tolerability signatures. End-user categorization highlights the pivotal role of cancer research institutes in early adoption, while hospitals and specialty clinics anchor broad-based commercialization efforts. Meanwhile, the contrast between intravenous and subcutaneous delivery channels underscores emerging opportunities for patient-centric treatment models and cost optimization in ambulatory settings.

Regional Dynamics Shaping Global Immunotherapy Adoption

Different geographic regions exhibit distinct trajectories in the adoption and reimbursement of checkpoint inhibitors. In the Americas, robust clinical infrastructure and supportive regulatory frameworks have fostered rapid uptake, particularly in high-incidence indications like lung and bladder cancer. Strategic partnerships between multinational corporations and regional health systems streamline launch sequences and facilitate expanded access programs.

Europe, Middle East & Africa present a heterogeneous landscape characterized by varying national health technology assessment processes and budget constraints. Progressive markets are implementing value-based procurement models, emphasizing real-world effectiveness and longitudinal patient outcomes. Emerging economies within this region are increasingly prioritized through tiered pricing and local manufacturing collaborations to enhance affordability.

In Asia-Pacific, dynamic growth is driven by rising cancer prevalence, expanding clinical trial activity, and evolving reimbursement policies. Key markets are investing in domestic biologics capacity while forging licensing agreements to accelerate market entry. The confluence of regulatory harmonization initiatives and patient advocacy efforts continues to strengthen the regional outlook for immuno-oncology agents.

Competitive Dynamics Driving Innovation and Market Presence

Leading pharmaceutical and biotechnology companies are shaping the competitive landscape through differentiated pipelines, strategic alliances, and targeted therapeutic development. Pioneers in CTLA-4 and PD-1 inhibition have reinforced market leadership by expanding indication labels and optimizing combination regimens with targeted therapies and chemotherapy backbones. Meanwhile, emerging players leverage novel molecular designs and bispecific platforms to address resistance mechanisms and broaden patient coverage.

Alliance strategies between small biotech innovators and large pharmaceutical enterprises are accelerating clinical development and driving geographic expansion. Concurrently, the pursuit of next-generation candidates, such as those with enhanced tumor microenvironment penetration or alternative checkpoint targets, underscores a commitment to sustained innovation. Companies investing in subcutaneous formulation technologies are primed to capture value through convenience-based differentiation, reducing infusion-related overhead and improving patient adherence.

Strategic Imperatives for Industry Leaders to Capitalize on Growth

Industry leaders must prioritize investment in biomarker-driven clinical programs to align therapeutic offerings with precision medicine imperatives. Establishing collaborative networks with academic research centers and patient advocacy organizations will enhance trial enrollment efficiency and strengthen evidence generation. To navigate cost pressures arising from the 2025 tariff adjustments, organizations should diversify manufacturing footprints and explore regional production partnerships.

Developing patient-centric delivery models, such as subcutaneous formulations and home infusion services, will address the growing demand for convenience without compromising clinical outcomes. Strategic licensing agreements and merger and acquisition activity can bolster portfolios in underserved indications, while value-based contracting arrangements with payers will safeguard market access through outcome-oriented reimbursement frameworks. By adopting a proactive, integrated approach across commercial, clinical, and regulatory domains, companies can secure sustainable growth in an increasingly competitive environment.

Rigorous Methodology Underpinning Our Research Findings

Our research methodology integrates a blend of secondary and primary data sources to ensure comprehensive and reliable insights. Initial desk research encompassed peer-reviewed publications, regulatory filings, corporate disclosures, and specialized databases to assemble a robust information base. This quantitative foundation was complemented by in-depth interviews with key opinion leaders, clinical investigators, and industry executives to validate assumptions and contextualize emerging trends.

Data triangulation was employed to reconcile disparate findings and enhance analytical rigor. Segmentation analyses were conducted using a top-down and bottom-up approach, enabling cross-verification of market dynamics from both macro and micro perspectives. Rigorous quality checks and peer reviews were implemented at each stage to uphold methodological integrity and ensure that the final report reflects the highest standards of market intelligence.

Synthesis of Key Findings and Strategic Outlook

This executive summary has distilled the pivotal drivers, challenges, and opportunities defining the immune checkpoint inhibitor market. From foundational scientific breakthroughs to tariff-driven market adjustments, the landscape is characterized by rapid innovation and complex competitive dynamics. Comprehensive segmentation and regional analyses reveal differentiated adoption patterns, underlining the importance of tailored strategies across indications, mechanisms, and geographies.

Competitive insights highlight the role of strategic alliances, pipeline diversification, and formulation innovations in sustaining growth and differentiation. Actionable recommendations underscore the need for biomarker-focused development, supply chain resiliency, and value-based collaboration with payers. Armed with these insights, stakeholders are empowered to make informed decisions that align clinical potential with commercial viability, ultimately advancing patient outcomes in oncology.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Bladder Cancer
    • Head And Neck Cancer
    • Melanoma
      • First Line
      • Second Line
    • Non Small Cell Lung Cancer
      • First Line
        • Combination Therapy
        • Monotherapy
      • Second Line
        • Combination Therapy
        • Monotherapy
    • Renal Cell Carcinoma
  • Mechanism Of Action
    • CTLA-4 Inhibitors
      • Ipilimumab
    • PD-1 Inhibitors
      • Cemiplimab
      • Nivolumab
      • Pembrolizumab
    • PD-L1 Inhibitors
      • Atezolizumab
      • Avelumab
      • Durvalumab
  • End User
    • Ambulatory Surgical Centers
    • Cancer Research Institutes
    • Hospitals
    • Specialty Clinics
  • Route Of Administration
    • Intravenous
    • Subcutaneous
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • AstraZeneca PLC
  • Pfizer Inc.
  • Merck KGaA

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Immune Checkpoint Inhibitors Market, by Indication
8.1. Introduction
8.2. Bladder Cancer
8.3. Head and Neck Cancer
8.4. Melanoma
8.4.1. First Line
8.4.2. Second Line
8.5. Non Small Cell Lung Cancer
8.5.1. First Line
8.5.1.1. Combination Therapy
8.5.1.2. Monotherapy
8.5.2. Second Line
8.5.2.1. Combination Therapy
8.5.2.2. Monotherapy
8.6. Renal Cell Carcinoma
9. Immune Checkpoint Inhibitors Market, by Mechanism of Action
9.1. Introduction
9.2. CTLA-4 Inhibitors
9.2.1. Ipilimumab
9.3. PD-1 Inhibitors
9.3.1. Cemiplimab
9.3.2. Nivolumab
9.3.3. Pembrolizumab
9.4. PD-L1 Inhibitors
9.4.1. Atezolizumab
9.4.2. Avelumab
9.4.3. Durvalumab
10. Immune Checkpoint Inhibitors Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Cancer Research Institutes
10.4. Hospitals
10.5. Specialty Clinics
11. Immune Checkpoint Inhibitors Market, by Route of Administration
11.1. Introduction
11.2. Intravenous
11.3. Subcutaneous
12. Americas Immune Checkpoint Inhibitors Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Immune Checkpoint Inhibitors Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Immune Checkpoint Inhibitors Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Merck & Co., Inc.
15.3.2. Bristol-Myers Squibb Company
15.3.3. Roche Holding AG
15.3.4. AstraZeneca PLC
15.3.5. Pfizer Inc.
15.3.6. Merck KGaA
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. IMMUNE CHECKPOINT INHIBITORS MARKET MULTI-CURRENCY
FIGURE 2. IMMUNE CHECKPOINT INHIBITORS MARKET MULTI-LANGUAGE
FIGURE 3. IMMUNE CHECKPOINT INHIBITORS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. IMMUNE CHECKPOINT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. IMMUNE CHECKPOINT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. IMMUNE CHECKPOINT INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY IPILIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 70. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 72. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 73. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 74. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 75. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 76. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 77. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 78. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 83. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 84. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 85. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 86. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 87. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 139. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 140. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 141. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 142. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 143. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 145. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 146. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 150. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 151. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 152. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 153. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 154. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 155. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 156. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 157. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 171. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 172. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 173. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 174. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 175. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 176. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 177. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 183. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 184. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 185. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 186. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 187. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 188. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 189. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 212. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 226. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 227. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 228. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 229. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 230. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 231. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 232. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 233. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 234. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 245. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 248. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 249. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 250. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 251. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 252. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 253. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 254. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 255. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 256. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 258. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 259. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 260. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 261. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 262. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 263. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 264. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 265. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 266. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 267. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 277. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 278. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 288. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 289. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 292. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 293. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 294. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 295. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 296. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 297. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 298. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 299. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 300. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 303. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 304. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 305. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 306. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 307. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 308. T

Companies Mentioned

The companies profiled in this Immune Checkpoint Inhibitors market report include:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • AstraZeneca PLC
  • Pfizer Inc.
  • Merck KGaA

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages196
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.64 Billion
Forecasted Market Value ( USD ) by 2030 $ 19.48 Billion
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned7

Related Topics

Related Reports

Immune Checkpoint Inhibitors - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Immune Checkpoint Inhibitors - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Immune Checkpoint Inhibitors Market Report by Type, Distribution Channel, Application, and Region 2025-2033 - Product Image

Immune Checkpoint Inhibitors Market Report by Type, Distribution Channel, Application, and Region 2025-2033

  • Report
  • 124 Pages
  • Global
From
Immune Checkpoint Inhibitors - Global Strategic Business Report - Product Image

Immune Checkpoint Inhibitors - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Report 2025 - Product Image

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Checkpoint Inhibitors Market Report 2025 - Product Image

Checkpoint Inhibitors Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Market

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs. Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.